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We  investigated  the  efﬁcacy  of a novel  microparticle  (MP)  based  vaccine  formulation  consisting  of per-
tussis  toxoid  (PTd),  polyphosphazene  (PCEP),  CpG  ODN  10101  and  synthetic  cationic  innate  defense
regulator  peptide  1002  (IDR)  against  Bordetella  pertussis  in  mice.  We  studied  whether  encapsulation
of  these  IDR-CpG  ODN  complexes  into  polyphosphazene-based  microparticles  further  enhanced  their
immunomodulatory  activity  compared  to  soluble  formulations  containing  PCEP  (SOL),  or without  PCEP
(AQ).  In  vitro  stimulation  of  murine  macrophages  showed  MP  induced  signiﬁcantly  higher levels  of  pro-
inﬂammatory  cytokines.  When  assessed  in  a B.  pertussis  infection  challenge  model,  a single  immunization
with  MP formulation  led  to  signiﬁcantly  lower  bacterial  loads  compared  to  other  formulations  and  non-
vaccinated  animals.  ELISPOT  of  splenocytes  showed  that  MP  group  mice  had  signiﬁcantly  higher  number
of  antigen-speciﬁc  IL-17  secreting  cells.  The  cytokine  proﬁle  in  lung  homogenates  of  MP  group  mice  afterdjuvants challenge  showed  signiﬁcantly  higher  amounts  of  MCP-1,  TNF-,  IFN-,  IL-12  and  IL-17 and  signiﬁcantly
lowered  IL-10  levels  suggesting  a strong  Th1  shift.  Protection  was  observed  against  challenge  infection
with  B.  pertussis.  On the  other  hand  protective  immune  responses  elicited  in  Quadracel® immunized  mice
were  Th2  skewed.  Hence,  we conclude  that  formulation  of PTd,  PCEP,  CpG  ODN  and  IDR  into  MP  generates
a  protective  immune  response  in mice  against  pertussis  emphasizing  the  potential  of  MP  as  a  delivery
vehicle  for  the potential  development  of  single-shot  vaccines.. Introduction
Effective immunization largely depends on the consideration
f immunogenic vaccine antigens and effective adjuvants. Most
ive attenuated or killed vaccines have been replaced by subunit
accines, which are safer but typically are less immunogenic and
hus require the presence of strong adjuvants that can induce
n early onset of immunity, long duration, and if needed, a shift
n the type of the response. Furthermore, the use of effective
djuvant platforms can also help to reduce the number of immu-
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nizations required, ideally to a single immunization only. Adjuvants
include a large group of molecules that can be divided into delivery
systems and immune modulators. Most often immune stimula-
tors are derived from pathogen associated molecular patterns
(PAMPs) also termed as ‘danger signals’ like bacterial unmethy-
lated CpG, LPS, ﬂagellin and viral double stranded RNA to name a
few. These PAMPs are recognized by cells of the innate immune
system, including antigen presenting cells, which express speciﬁc
pathogen recognition receptors (PRRs) such as Toll like receptors
(TLRs).
In the present study, we evaluated a novel vaccine platform con-
taining CpG ODNs, polyphosphazenes and cationic innate defense
regulator peptide (IDR) 1002. CpG ODNs have been studied exten-
Open access under CC BY-NC-ND license.sively in regards to their immune stimulatory activities and are
well characterized as vaccine adjuvant in both preclinical and
clinical studies [1]. CpG ODN act through TLR9, expressed on
human plasmacytoid DCs and B-cells [2], and favor induction of a
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ro-inﬂammatory Th1 immune response. Thus, CpG ODN has
een used as adjuvants to promote a Th1 or mixed Th1/Th2
esponse in experimental vaccines against various diseases [3,4].
nterestingly, CpG ODNs have shown greater adjuvanticity when
o-administered with other adjuvants [5,6]. In the present study,
pG ODNs were co-formulated with synthetic innate defense
egulator (IDR) peptides, which have well documented selec-
ive immune stimulatory activities that include protection against
nfections, chemokine induction leading to the recruitment of
eukocytes, wound healing, modulation of apoptosis, and anti-
nﬂammatory activities [7,8]. IDRs are synthetic mimics of host
efense peptides, which represent important components of
he innate immune system and these peptides also enhance
nd modulate adaptive immune responses [9,10]. We  previ-
usly demonstrated this adjuvantation with a pertussis vaccine
11].
Polyphosphazenes are an emerging class of well-deﬁned
acromolecules that combine immune stimulatory activity and
ose-sparing effects with the ease of their assembly into supra-
olecular MP  structures to achieve optimal delivery [12]. Several
tudies have demonstrated the adjuvant activity of polyphosp-
azenes including formulation with IDR and CpG ODN: however,
ll of these studies used soluble polyphosphazenes. Here, we report
he development of polyphosphazene microparticles as a means to
reate depots at the site of injection, facilitate uptake by antigen-
resenting cells, and potentially allow delivery via the mucosal
urfaces [13].
.  Materials and methods
.1.  Antigen and adjuvants
PTd  was kindly provided by Novartis vaccines (Sienna, Italy).
oly [di (sodium carboxylatoethylphenoxy) phosphazene] (PCEP)
f MW 108 g/mol was synthesized at Idaho National Laboratory,
daho Falls, ID, USA. Phosphorothioate-stabilized single stranded
pG ODN (TCGTCGTTTTCGCGCGCGCGCCG) was  provided by Pﬁzer
Ottawa, ON, CAN). IDR peptide (VQRWLIVWRIRK) was  synthesized
t GENSCRIPT, USA Inc. (Picataway, NJ, USA).
.2. Formulation and scanning electron microscopy
The CpG ODN 10101 and IDR 1002 were complexed in a ratio
f 1:2 (w/w) at 37 ◦C for 30 min  and PCEP was added along with
he PTd antigen to obtain the SOL formulation resulting in a ratio
f 1:2:1 (w/w/w) ratio of PCEP:IDR:CpG ODN. The AQ formulations
ere made as above but without PCEP. The MPs were formulated
y the drop-wise addition of 0.2% of NaCl to the SOL formulation
escribed above, incubated for 20 min  at RT and this emulsion was
dded to 8.8% CaCl2 and stirred for 10 min. The MP was  collected by
entrifugation at 1340 × g for 10 min  and washed with de-ionized
ater, and collected by centrifugation as described above. The
upernatants and washes were collected, pooled and the amount of
nincorporated CpG ODN was estimated by QUBIT® ssDNA assay kit
Invitrogen), the unincorporated IDR was estimated by HPLC, and
he PTd by QUBIT® protein assay kit (Invitrogen). The formulations
ere stored at 4 ◦C. The encapsulation efﬁciency was estimated
s, E = [(total amount of analyte − amount of analyte in the super-
atant and washes)/(total amount of analyte)] × 100 where analyte
s either PTd, CpG-ODN or IDR 1002. The surface morphology and
ize of the MP  was analyzed by scanning electron microscopy
SEM; JM4500, Jeol, Japan) at 1000×, 5000× and 20,000× magni-
cation and the images were processed by using ImageJ freeware
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2.3.  In vitro stimulation of mouse J774 macrophages with
PCEP-IDR-CpG ODN formulations
Mouse J774 cells (ATCC, VA, USA) were seeded at 2 × 106 cells in
DMEM (Sigma D5546) supplemented with 10% fetal bovine serum
in 24-well tissue culture plates (FALCONTM; Beckton, Dickinson and
Company) and the formulations were overlaid on the cells in trip-
licates and incubated at 5% CO2 at 37 ◦C for 48 h. The formulations
used were: (1) MP-CpG ODN-IDR (MP-complexed), (2) mixture
of MP-IDR and MP-CpG ODN (MP-uncomplexed), (3) PCEP + CpG
ODN + IDR (SOL-complexed), (4) CpG ODN + IDR (AQ-complexed),
(5) E. coli lipopolysacharide (LPS) and (6) medium alone. The above
formulations contained 10 g of PCEP, 10 g CpG ODN and 10 g
or 20 g of IDR per well. The supernatants were collected by cen-
trifugation at 8500 × g for 10 min  to obtain cell-free supernatants
and stored by freezing at −20 ◦C. The amount of secreted MCP-
1, TNF-, IL-6 and IL-12p40 were assayed using sandwich ELISA
DUOSET® (Research and Diagnostics Systems, MN,  USA) as per the
manufacturer’s instructions.
2.4.  Immunization of mice
Cohorts of 6–8 week old female BALB/c mice were obtained from
Charles River Laboratories (St. Constant, QC). All experiments were
conducted in accordance with the ethical guidelines by the Uni-
versity of Saskatchewan and the Canadian Council for Animal Care.
The mice (n = 12 per group) were given a single immunization by
subcutaneous injection on the back with formulations containing
10 g of PCEP, 20 g of IDR 1002, 10 g CpG ODN  10101 as SOL,
MP or AQ formulations, with Quadracel® (Sanoﬁ-Pasteur) diluted
to 1 g of PTd per animal and one group received only phosphate
buffered saline pH 7.4 (PBS). The mice were immunized on day 1
and serum was separated from blood collected by tail vein puncture
on days 14 and 28 after immunization.
2.5. B. pertussis challenge
B.  pertussis Tohoma-1 strain were streaked onto charcoal agar
plates supplemented with 10% sheep blood (CBA) and incubated at
37 ◦C for 48 h to obtain single colonies. A few single colonies were
subsequently spread onto fresh CBA plates and incubated as above.
After 48 h, plates were overlaid with 300 l of 1% casamino acids,
bacteria were scraped off into the casamino acid solution and 200 l
of the suspension was used to inoculate fresh CBA plates. These
were incubated and harvested as described above and transferred
into 2 ml  of SS medium and quantiﬁed using a spectrophotometer.
Bacterial concentration was  adjusted to 5 × 106/20 l and admin-
istered intranasally. After 2 h, 2 animals from each group were
humanely euthanized and their lungs were collected and homog-
enized in 1 ml  of SS medium and 10-fold dilutions were plated on
CBA agar plates to determine the number of viable bacteria. Lungs
from 5 mice per group were collected at days 3 and 7 after chal-
lenge and processed as described above. The lung homogenates
were stored in 0.1 mg/ml  of PMSF at −20 ◦C and used to exam-
ine MCP-1, TNF-, IL-12p40, and IFN- cytokine production and to
evaluate total IgG and IgA antigen-speciﬁc antibody responses.
2.6.  Analysis of PTd speciﬁc antibody titers
Antigen speciﬁc total IgG, IgG1, IgG2a and IgA immune
responses were determined by end-point ELISA using methods
previously described [14]. Brieﬂy, 100 l of pertussis toxin (PT,
Sigma–Aldrich Inc., CA, USA; 0.25 g/ml) in carbonate coating
buffer (15 mM  Na2CO3, 35 mM NaHCO3, pH 9.6) was  added to each
well. Wells were washed 6 times with Tris-buffered saline pH 7.3
(TBS) containing 0.05% TWEENTM 20 (TBS-T). Diluted mouse serum
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amples (for IgG1 and IgG2a) or lung homogenates (IgG and IgA)
ere added to the wells at 100 l/well and incubated for 1 h at room
emperature. Wells were washed again with TBS-T and biotinylated
oat-anti mouse IgG, IgG1, IgG2a, and IgA antibodies (Caltag Lab-
ratories, CA, USA) were added to wells (1/5000) at 100 l/well
nd incubated for 1 h at room temperature. Wells were washed
nd alkaline phosphatase conjugated with streptavidin (Cedarlane
aboratories, ON, CAN) diluted 1/5000, was added in each well fol-
owed by 1 h incubation at room temperature. Wells were washed
 times in double distilled water (ddH2O). Di(Tris) p-nitrophenyl
hosphate (PNPP) (Sigma–Aldrich Inc.) was diluted 1/100 in sub-
trate buffer (1 mM of MgCl2, 200 mM of Tris–HCl, pH 9.8) and
00 l/well was added. The reaction was allowed to develop for
5 min, and absorbance was read as optical density (OD) at 405 nm
n a Microplate Reader (Bio-Rad Laboratories Inc., CA, USA). Results
re reported as titers, which are the reciprocal of the highest dilu-
ion that gave a positive OD reading. A positive titer was deﬁned as
n OD reading that was at least two times greater than the values
or a negative sample obtained from naive mice.
.7. Isolation of splenocytes
Spleens  were collected 3 and 7 days after challenge and placed
n cold, minimal essential medium (GIBCO®, Carlesbad, CA, USA).
he spleens were sieved through a 40 m nylon cell strainer (BD
ALCON, San Jose, CA, USA) using scissors and a syringe plunger.
 ml  of sterile NH4Cl lysis buffer was added to the cell suspen-
ion to lyse the erythrocytes for 1 min  and lysis was  stopped by
mmediately topping up the 15 ml  tube with MEM. The spleno-
ytes were washed once with MEM  medium and resuspended in
omplete AIM V medium (incomplete AIM V, 0.1 mM  non-essential
mino acids, 1 mM sodium pyruvate, 10 mM HEPES, 1× antibiotic
en strep, 1% FBS, 20 m l-glutamine, 50 m 2-mercaptoethanol)
o a ﬁnal concentration of 1 × 107 cells/ml. Cells were counted
sing a MULTISIZERTM 3 COULTER COUNTER® (Beckman Coul-
er, ON, Canada) according to the manufacturer’s instructions. Cell
oncentrations were determined using software provided by the
anufacturer.
.8. Detection of PTd-speciﬁc cytokine-producing cells by ELISPOT
Nitrocellulose microtiter plates (Whatman, Florham Park, NJ,
SA) were coated with 1.25 g/ml puriﬁed rat anti-mouse IL-4 and
FN- capture monoclonal antibodies (BD Biosciences, Mississauga,
N, Canada) in coating buffer for 16 h at 4 ◦C. Plates were washed
nd blocked with complete AIM V medium (GIBCO) in a 37 ◦C incu-
ator. Splenocytes (1 × 106 cells/well) were added in triplicates.
Td antigen (1 g/well) was added and incubated at 37 ◦C for 18 h.
ell suspensions were removed and 1.25 g/ml puriﬁed biotiny-
ated rat anti-mouse IL-4 and IFN- monoclonal antibodies (BD
iosciences) diluted in PBS and 0.1% Tween-20 (PBST) at 1.25 g/ml
ere added to each plate and incubated for 16 h at 4 ◦C. Plates were
ashed with PBST and a streptavidin alkaline phosphatase/glycerol
olution was added to the plates at 1/500 dilution in PBST for 1.5 h
t room temperature. The plates were washed 8 times with ddH2O
nd 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium
NBT/BCIP) (Sigma) insoluble alkaline substrate solution was added
o all plates for 5 min  at RT. Plates were ﬁnally washed with ddH2O
nd left to dry at RT. Spots were counted manually using a Stemo
000 inverted light stereomicroscope (Zeiss, Toronto, ON, Canada).
.9. Statistical analysisThe  data were analyzed and graphed using GraphPad Prism
ersion 5.01 for Windows®, (GraphPad Software Inc., San Diego,
A, USA, www.graphpad.com). The data were not normally9 (2011) 6540– 6548
distributed and hence statistical signiﬁcance was  tested using
the Kruskal–Wallis test. When the results were signiﬁcant, dif-
ferences among the individual medians were examined using
the Mann–Whitney test. Signiﬁcant effects were declared when
P < 0.05.
3. Results
3.1. MP characterization and scanning electron microscopy
The incorporation efﬁciency of PTd in the MPs  was  estimated to
be around 78% for PTd and 95% for CpG and HDP. Previous studies
showed that particles less than 10 m are preferentially taken up
by APC [12,15,16]. As such, SEM of MPs  that comprised of PCEP with
CpG ODN, and IDR-1002 was  performed to ensure that the resulting
size of the particles was compatible with uptake into APC to ensure
that an effective dosage of antigen would be processed. Our  previ-
ous studies of encapsulated CpG ODN using the same methodology
not only showed that the MPs  generated were less than 10 m, but
also revealed 99% uptake into murine macrophages [12,15]. Indeed,
the addition of IDR-1002 into the MP  was  consistent with these pre-
vious ﬁndings revealing particles ranging in size from 0.5 to 5 m
in diameter (Fig. 1A and B). At higher magniﬁcation (20,000×), a
close inspection of the surface of these MP  revealed that it was  not
smooth; instead, the surface of these MP  seem to be composed of
smaller nanoparticle structures (Fig. 1C).
3.2. In vitro release of chemokines and cytokines from mouse
macrophages treated with CpG ODN and IDR in MP  and soluble
formulations
To  assess the efﬁcacy of MP  formulation, we  compared the lev-
els of the pro-inﬂammatory cytokines TNF, IL-6 and IL-12p40
in murine J774 macrophages treated with CpG ODN-IDR (AQ),
PCEP-CpG ODN-IDR (SOL) and MP  co-encapsulating PCEP-CpG
ODN-IDR. Other than measuring pro-inﬂammatory responses, we
also looked for the chemokine MCP-1, a chemotactic agent for
monocytes/macrophages, T cells, NK cells, and neutrophils, since it
was  previously shown that both CpG ODN and the IDR-HH2 alone
enhanced MCP-1 production [17], while their complexes demon-
strated a synergistic increase in production [11]. The induction of
MCP-1 was strongest with the SOL formulation compared to the MP
formulation (Fig. 2A) co-encapsulating CpG ODN-IDR complexes
or CpG ODN and HDP delivered in uncomplexed MP.  The release
of pro-inﬂammatory cytokines TNF- and IL-6 was  signiﬁcantly
higher in MP  treated macrophages than AQ or SOL formulation
treated groups (Fig. 2B and D). The IL-12p40 levels were two-
fold higher in the MP  than SOL or AQ formulation treated groups
(Fig. 2C). LPS was used as a positive control to demonstrate the
viability of the cells. Based on these results, we conclude that the
MP delivery induced higher levels of pro-inﬂammatory cytokines
in mouse macrophages.
3.3.  Systemic antibody induction following parenteral
immunization with PTd antigen entrapped in MP or in solution
Encouraged by an enhanced pro-inﬂammatory in vitro response,
the adjuvant formulation of PCEP:IDR:CpG ODN was tested in an
in vivo mouse pertussis challenge model with the inclusion of
PTd antigen in SOL (PCEP-IDR-CpG ODN-PTd), MP  (PCEP-IDR-CpG
ODN-PTd) and AQ (IDR-CpG ODN-PTd) formulations and com-
pared with commercial acellular pertussis vaccine containing
PTd, FHA, ﬁmbrial antigens and with alum adjuvant (Quadracel®).
To examine the effects of MPs  in vivo, we assessed the levels of
IgG1 and IgG2a PTd-speciﬁc antibody levels in sera at 14 and 28
days post immunization. At day 14, it was observed that animals
S. Garlapati et al. / Vaccine 29 (2011) 6540– 6548 6543
Fig. 1. Scanning electron micrographs of PCEP MPs  encapsulating CpG ODN-IDR-PTd. The lyophilized MP  was examined at magniﬁcation of 1000× (A), 5000× (B) and 20,000×
(C).
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edian of the IgG1/IgG2a ratio of individual animals showing the degree of Th2 shift
ange. Statistical signiﬁcance at each time point from PBS control group was analyze
mmunized with Quadracel®, SOL and AQ formulations showed
igniﬁcantly higher amounts of IgG1 antibodies than the negative
ontrol (Fig. 3A). At day 28, the IgG1 levels were similar in groups
f mice immunized with Quadracel® SOL and AQ formulations
Fig. 3A). The levels of IgG1 in the MP  group were 10 times lower
han other groups. At day 28, IgG2a levels were signiﬁcantly higher
n SOL group than all the other groups, and were about 10 times
ess in both AQ and MP  groups. Expectedly, Quadracel® induced
nly weak IgG2a responses (Fig. 3B). In contrast, IgG2a responses
ere almost non-detectable in the Quadracel group, and about
00–1000 fold higher in mice immunized with microparticle-
ased or soluble adjuvant formulations. The ratio of IgG2a and
gG1 was 1.58 in mice immunized with MP  and was lower than
 in mice immunized with Quadracel®, AQ and SOL formulations
Fig. 3C). Interestingly the ratio of IgG2a and IgG1 titers was
ore than 1000-fold lower in mice immunized with Quadracel®
ndicating a Th2 skew in this group.
.4. Induction of T-cell responses by ELISPOT of splenocytes
To  conﬁrm if the antigen-speciﬁc antibody response was consis-
ent with a cell-mediated response, the splenocytes of challenged
ice were stimulated with PTd to assay the number of cells secret-
ng IFN- and IL-4 by ELISPOT assay. The absolute number of IFN-
pots in the SOL and MP  formulations were signiﬁcantly higher as
ompared to Quadracel® and AQ formulations (Fig. 4A). In contrast,
he absolute number of IL-4 spots were higher in the Quadracel®
roup indicating that the presence of CpG and/or IDR in AQ, SOL, MP
roup shifted the immune response towards a Th1-type which was
ore clear when the ratio of IFN- and IL-4 spots were examined
Fig. 4C). While the ratio of 0.48 for Quadracel® reﬂected a pre-
ominantly Th2 response, the ratio was 0.8 and 1.0 for AQ and SOL
roups, demonstrating that the presence of CpG ODN-IDR adjuvantays 14 and 28 and IgG1 and IgG2a isotype antibodies estimated by ELISA. (C) The
ibody responses. The bars represent the median of antibody titers with interquartile
ruskal–Wallis test followed by Mann–Whitney test. *P < 0.05; **P < 0.01;***P < 0.001.
complexes  in the formulations induced more of a Th1 response.
Importantly, the MP  group had a ratio of 1.78, indicating a strong
Th1 shift. We  also looked at Th17 responses as it has been docu-
mented that IL-17 mediates the clearance of pathogens from airway
epithelium [18,19]. The number of IL-17 spots detected was statis-
tically signiﬁcantly higher in the MP  group (Fig. 4D).
3.5.  Bacterial clearance from lungs and IgA/IgG levels after
intranasal B. pertussis challenge
Ultimately, whether an immune response is through induction
of antibodies or cytokines, the best indicator for vaccine efﬁcacy is
its ability to clear the infectious agent, in this case B. pertussis. This
was tested in an intranasal challenge with B. pertussis. Mice immu-
nized with the microparticle-based adjuvant formulation displayed
about 100 fold lower bacterial burden at day 7 post infections. Simi-
lar to mice immunized with Quadracel (Fig. 5). In contrast, the mice
in SOL and AQ groups failed to reduce the bacterial burden in the
lungs and had similar bacterial burden as in the control group. Co-
encapsulation of SOL components in MP  enhanced their protective
efﬁcacy. One of the most interesting observations in this study was
the levels of IgG and IgA antibodies in the lungs after challenge.
The levels of both PTd speciﬁc IgA and IgG in the MP  group were
signiﬁcantly higher than all other groups (Fig. 6).
3.6.  Cytokine production in lungs after challenge
The levels of MCP-1 in the lung homogenates were higher in
both SOL and MP  group in comparison to Quadracel® or AQ formu-
lations at day 3 after challenge (Fig. 7A). After 7 days we detected
twice the amount of MCP-1 in the MP  group compared to the SOL
group. Hence the persistence of MCP-1 was extended after chal-
lenge in the MP  group. Analysis of TNF-, IL-10, IFN- and IL-12p40
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ytokines showed that immunization with MP  induced a predom-
nantly Th1-type response in the lungs (Fig. 7B–E). Quadracel®
roduced a predominantly Th2-type of response. The levels of IL-
0 were lower in all groups other than Quadracel® but surprisingly
he levels rebounded to that of Quadracel® at day 7 in SOL. Further-
ore, IL-17 levels in lungs from Quadracel® and MP  immunized
ice were signiﬁcantly higher than AQ or SOL groups (Fig. 7F).
e conclude that immunization with MP  induced higher levels ofh1 and Th17 type cytokines, while immunization with Quadracel®
nduced more Th2 type cytokines.
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 PBS control group was analyzed by Kruskal–Wallis test followed by Mann–Whitney
mber of spots of IFN-/IL-4 for each group.
4. Discussion
In this study we  found that a single subcutaneous immuniza-
tion with MPs  co-encapsulating CpG ODN, IDR and PCEP along with
PTd provided better protection against pertussis than these com-
ponents given in soluble formulation. The co-encapsulation of the
adjuvants and the antigen in MP  provided a signiﬁcantly higher
Th1 and Th17 type response in the lung in spite of lower systemic
humoral responses.Multi-component vaccine formulations require an effective
delivery system for co-delivery of all components to the immune
cells and tissues to generate a desired response. As such, in the
present work we  used the polyphosphazene adjuvant PCEP in com-
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ination with complexes of CpG ODN and IDR for delivering PTd as
 model antigen against pertussis. The formulation was delivered
n two ways, either as a soluble ad-mixture of all the components
SOL) or co-delivered in MPs  in which PCEP itself was  used as an
ncapsulating agent without the need for additional component
or encapsulation. Here, we found that the MP  group had about
00 times lower bacterial burden in the lungs compared to non-
mmunized mice.
The  advantage of using MP  as a tool is that particulate delivery
ncreases vaccine stability and uptake of the antigen to the MHC
lass I and class II compartments resulting in induction of both
ell-mediated and humoral immune responses [20]. Historically,
oly(lactic-co-glycolic acid) (PLGA), MPs  and/or nanoparticles have
een investigated extensively as delivery systems. PLGA MPs  have
een moderately successful in delivering various protein antigens,
NA, siRNA as well as cytokines. Unfortunately, their usefulness
s limited by the lack of stability, complex preparation methods,
igh capital investment, and the use of organic solvents which may
ompromise the immunogenicity of antigens and may  be poten-
ial carcinogens. However, polyphosphazene MPs  are prepared by
 simple step coacervation with NaCl and ionic cross-linking with
aCl2 [21]. This methodology can be commercially scalable andS control at each time point was  analyzed by Kruskal–Wallis test followed by
does  not require complex manufacturing equipment, elevated tem-
peratures, risk of aerosol generation or the use of organic solvents.
The release kinetics of antigen and adjuvants from MP can be con-
trolled to pulsatile or sustained release, a characteristic that makes
single-shot vaccines a real possibility [22].
Mice vaccinated with MPs  had signiﬁcantly reduced bacterial
burden though they had 10-fold lower antibody responses. The pro-
tection levels were similar to that of Quadracel which contains four
additional antigens. These results are consistent with clinical trials
demonstrating that ﬁve-, three- and most two  component vaccines
are more efﬁcacious than a monocomponent chemically detoxiﬁed
PTd vaccine [23]. Clearly, our formulation could be improved by the
inclusion of additional pertussis antigens.
Protection against pertussis is mediated by both humoral and
cell-mediated immunity and evidence suggests that cell-mediated
immunity is critical for protection [24]. For example, protection
is maintained among children whose antibody levels drop below
the level of detection over time [25] suggesting that cell-mediated
immunity is an important component of protection. Cell-mediated
immune responses remain measurable substantially longer than
antibodies to the same antigens, particularly PTd, and the cell-
mediated immune responses to initial doses of pertussis vaccines
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re believed to correlate better with long-term immunity than anti-
ody responses [23]. Here we demonstrated a microparticle-based
accine adjuvanted with CpG-ODN IDR and polyphosphazenes
nduce a strong shift towards Th1 type responses.
To address why animals immunized with MPs  were more efﬁ-
acious in bacterial clearance, we looked at the levels of IgG and IgA
ntibodies in the lung homogenates after challenge. To our surprise
e found that their levels were the highest in MP  groups which may
ave enhanced macrophage killing of antibody-opsonized bacteria.
t has been reported in the literature that IgG opsonized B. per-
ussis was efﬁciently phagocytosed by human polymorphonuclear
ells (PMN) mediated by the PMN  IgG FcRIIa and FcRIIIb recep-
ors [23]. Similarly, bacteria opsonized with IgA triggered similar
MN activation via FcR. In the same study it was also shown that
imultaneous opsonization of bacteria with both IgA and IgG led
o enhanced bacterial clearance compared to either of the isotypes
lone. It was also reported that FcRI-mediated binding, phagocy-
osis, and bacterial killing by PMN  originating from human FcRI-
ransgenic mice as this receptor is absent in mice [26]. However,
he absence of this receptor does not prevent the binding of IgA
o mouse PMN  [27] and suggest alternative receptors on PMN  for
psonization via IgA. Hence, we postulate that immunization with
Ps  induced signiﬁcantly higher levels of IgG and IgA in the lungs,
hich subsequently contributed to enhanced bacterial killing.
The  IgG and IgA in the lungs were higher in MP group than SOL
hough the serum antibody levels were lower in MP  group. This
ay be because of enhanced priming by the MP  than by SOL for-
ulation leading to increased levels of local antibody response in
he lungs after challenge in the former. These can be further sup-
orted by higher levels of serum antibody levels observed after a
ooster immunization (unpublished results) than in a single shot
s described in the present study. This may  be due to better B-cell
emory induced by MP  formulation.
Earlier studies on the mechanisms that prevent replication,
issemination and eventual clearance of B. pertussis from the
espiratory tract appear to reﬂect the dual extra- and intracellu-
ar location of the bacteria in the host and require the distinct
ut coordinated functions of the cellular and humoral arms of
he immune responses for optimal protection [28]. The levels of
ro-inﬂammatory cytokines TNF-, IL-12p40 and the chemokine
CP-1 were signiﬁcantly higher only in the lungs of mice in the
P group. This could have been likely due to the adjuvant effect
f CpG ODN and IDR peptide in the formulation, respectively. We
elieve that the MP-complexed formulation showed higher pro-
nﬂammatory response compared to the SOL and AQ formulations
ecause of possible better synergy due to delivery of PTd, CpG
DN and IDR peptide in the MP  formulation to the same APC.
his synergy is reﬂected by our in vitro study where in mouse
acrophages, PCEP MP  formulation containing CpG ODN and IDR
eptides produced higher pro-inﬂammatory response as com-
lexed or uncomplexed using PCEP:IDR:CpG ODN ratio of 1:2:1.
The  higher amount of pro-inﬂammatory cytokines in the lungs
s known to regulate the selective induction of Th1 cells and secre-
ion of cytokines such as IFN- (Th1) and IL-17 (Th17). Cytokines
ecreted by Th1 cells, especially IFN-, provide help for opsonizing
ntibody production and activate macrophages and neutrophils to
ake up and kill intracellular B. pertussis bacteria. The Th1 responses
re characteristics of immune responses in children and mice
mmunized with whole cell pertussis vaccine (Pw) [29,30]. The
cellular pertussis vaccines, however, are devoid of bacterial toxins
hat stimulate pro-inﬂammatory cytokines but consists of compo-
ents like FHA, which stimulate IL-10 production and consequently
ave anti-inﬂammatory activity and preferentially induce Th2 cells.
h2 cells provide help to B-cells to secrete IgE and murine IgG1
ntibodies, which neutralize toxins and prevent adherence of bac-
eria in the respiratory tract. The levels of IL-10 were signiﬁcantly
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higher  in Quadracel® group with very low amount of IFN- and
IL-12p40, signifying a predominantly Th2 response. Both SOL and
MP generated signiﬁcantly higher amounts of IL-12p40 and IFN-
and lower amount of IL-10 showing a clear Th1 shift. Interestingly,
7 days after challenge, the IL-10 levels rebounded in the SOL group
to levels comparable to that of Quadracel®. Thus, the MP  formula-
tion seems to maintain the Th1 response for a longer duration than
SOL formulation.
In  summary, we demonstrated that immunization with PTd
encapsulated into microparticles and adjuvanted with CpG ODN
and IDR induced strong Th1 responses and partial protection
against challenge with B. pertussis. From here on, future studies will
determine whether inclusion of additional antigens like Pertactin
and/or FHA in our formulations may  result in enhanced protection
comparable to commercial acellular or cellular vaccines in a single
shot model.
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